Patrick Walsh, a distinguished figure in the CDMO sector and Operating Partner at Ampersand Capital Partners, steps in as the new Executive Chairman of MedPharm Ltd. The board also welcomes Minor Hinson, representing Bourne Partners Strategic Capital, as a new member. These appointments underscore MedPharm’s commitment to steering the company into its next growth phase with seasoned expertise and innovative strategies.
David Parker is a General Partner of Ampersand Capital Partners, which he joined in 1994. Prior to Ampersand, David was a management consultant at Bain & Company and Mercer Consulting, and a corporate lender at First National Bank of Boston. Mr. Parker currently serves on the Boards of Directors of Bioventus, Detector Technologies, Gyros Protein Technologies and MedPharm. His prior Board Directorships have included Avista Pharma, ACLARA Biosciences, Assay Designs, NOVEX, Roadrunner Pharmacy and Signature Genomic Laboratories. David currently heads Ampersand’s European office, which is based in Amsterdam.
Minor Hinson is a Senior Managing Director and the Chief Investment Officer of Bourne Partners Strategic Capital (“BPSC”). Over the course of his career, Minor has been involved in financial transactions totaling over $10 billion, including venture investing, private equity, mezzanine and senior debt, project finance debt and equity, cross boarder preferred stock issuances, sell-side and buy-side M&A transactions (both large cap and middle market) and other corporate finance advisory assignments. Minor has also served on the Board of Directors for a number of companies over his career. Minor received a B.A. in Economics from Davidson College in 1984, as well as an M.B.A. (honor society) in 1992 from The Kenan-Flagler Business School at UNC Chapel Hill.
Trevor Wahlbrink is a Partner of Ampersand Capital Partners, which he joined in 2012. Prior to Ampersand, Mr. Wahlbrink was an investment banker at Morgan Keegan and Covington Associates where he advised on merger and acquisition and capital raising transactions for middle market healthcare and technology companies. Mr. Wahlbrink currently serves on the Boards of Directors of Confluent Medical and MedPharm. His prior Board Directorships have included Avista Pharma, Corpus Medical, Elite One Source Nutritional Services and ETE Medical. Mr. Wahlbrink is based in Ampersand’s Wellesley, MA USA offices.
Wendy brings over 20 years of experience in human resources leadership, specializing in employee relations, compensation, and benefits administration. She is passionate about cultivating a positive and inclusive workplace culture that supports employee engagement and organizational growth.
Throughout her career, Wendy has worked across diverse industries, consistently aligning HR strategy with business objectives to drive performance and enhance the employee experience. Her expertise spans talent development, policy implementation, and change management, with a strong focus on fostering transparent communication and trusted working relationships at every level of the organization.
Dave Haas brings over 25 years of experience in life sciences manufacturing, laboratory operations, and enterprise systems implementation. He leads MedPharm’s global IT strategy, with a focus on driving digital transformation, enhancing operational scalability, and optimizing the customer experience across the organization.
Before joining MedPharm, Dave held senior technology leadership roles at BioAgilytix, Alcami Corporation, BestCo, and Endo Pharmaceuticals. Throughout his career, he has successfully led complex, cross-functional implementations of core enterprise platforms—including SAP, LabVantage, and NuGenesis—and delivered transformational outcomes across quality systems, computer system validation, and corporate project management.
Jackie Moore is the VP of Finance for MedPharm, where she leads MedPharm’s global finance organization, which includes accounting and reporting, tax, treasury, audit, and financial planning and analysis. Jackie has spent her career providing finance, accounting, and business operations support and operational efficiencies to life science companies, including Expression Analysis, Inc. (acquired by Quintiles Transnational), INC Research (now Syneos Health), and Avista Pharma Solutions, Inc. (acquired by Cambrex).
Jackie holds a BS in Biological Business Management and a minor in Economics from North Carolina State University.
Stephanie Proesel is a dynamic leader in business strategy with over 25 years of experience across the biotech, medical device, and martech sectors. As Vice President of Sales and Marketing at MedPharm, she leverages her expertise to drive innovative growth strategies and enhance operational performance.
Before her tenure at MedPharm, Stephanie held significant roles, including President at Graylinc and various leadership positions at Merz Aesthetics. There, she was instrumental in directing global market intelligence initiatives, overseeing substantial revenue growth, and launching successful marketing campaigns that solidified the company’s market presence.
Armando Cortes is a seasoned pharmaceutical operations and biotechnology executive with over 30 years of industry experience spanning quality, manufacturing, and global operations. As Executive Vice President of Quality and Operations at MedPharm, he brings a proven track record in leading high-performing teams and driving excellence across small volume parenteral, API, and solid oral dosage form manufacturing environments.
Armando began his career in research and development at DuPont Pharmaceuticals before relocating to the Netherlands to lead a biotech start-up. He has since held a series of senior leadership roles with increasing responsibility in both domestic and international settings, managing traditional and multicultural workforces across single and multi-plant facilities. His deep expertise includes FDA compliance, quality system optimization, and operational turnarounds in regulated manufacturing environments.
